X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10231) 10231
Book Review (1735) 1735
Publication (1295) 1295
Government Document (104) 104
Book Chapter (80) 80
Conference Proceeding (37) 37
Dissertation (26) 26
Magazine Article (14) 14
Web Resource (6) 6
Book / eBook (4) 4
Trade Publication Article (4) 4
Data Set (2) 2
Newspaper Article (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8441) 8441
humans (8354) 8354
female (7000) 7000
oncology (4827) 4827
breast neoplasms - genetics (4665) 4665
breast cancer (4405) 4405
mutation (4323) 4323
middle aged (3564) 3564
adult (3404) 3404
genes, brca1 (3321) 3321
genes, brca2 (3320) 3320
brca2 (3302) 3302
cancer (2829) 2829
genetic predisposition to disease (2652) 2652
brca1 (2544) 2544
ovarian neoplasms - genetics (2460) 2460
brca2 protein - genetics (2341) 2341
genetic aspects (2326) 2326
aged (2271) 2271
risk factors (2234) 2234
ovarian-cancer (2171) 2171
ovarian cancer (2156) 2156
women (2128) 2128
brca1 protein - genetics (1941) 1941
risk (1929) 1929
genetics & heredity (1765) 1765
brca2 protein (1686) 1686
male (1630) 1630
research (1492) 1492
breast-cancer (1475) 1475
genetic testing (1413) 1413
genes (1384) 1384
gene mutations (1155) 1155
health aspects (1134) 1134
mutations (1132) 1132
germ-line mutation (1119) 1119
genetics (1065) 1065
brca2 mutations (942) 942
brca1 protein (923) 923
heterozygote (921) 921
breast neoplasms - pathology (911) 911
germline mutations (901) 901
breast neoplasms - epidemiology (878) 878
skin and connective tissue diseases (865) 865
article (854) 854
dna repair (839) 839
breast (832) 832
breast neoplasms - diagnosis (821) 821
susceptibility (817) 817
risk assessment (802) 802
genetic counseling (796) 796
neoplasm proteins - genetics (794) 794
medicine & public health (783) 783
analysis (782) 782
carriers (782) 782
prognosis (777) 777
aged, 80 and over (771) 771
pedigree (764) 764
brca2 mutation carriers (755) 755
tumors (741) 741
breast neoplasms - prevention & control (737) 737
animals (734) 734
obstetrics & gynecology (734) 734
transcription factors - genetics (726) 726
surgery (721) 721
families (694) 694
diagnosis (686) 686
gene (682) 682
genetic screening (671) 671
homologous recombination (667) 667
biochemistry & molecular biology (647) 647
prevalence (636) 636
carcinoma (633) 633
dna mutational analysis (621) 621
care and treatment (619) 619
endocrine system diseases (618) 618
family-history (614) 614
epidemiology (606) 606
abridged index medicus (604) 604
population (602) 602
survival (589) 589
oncology, experimental (586) 586
brca (572) 572
genetic research (556) 556
young adult (556) 556
dna damage (555) 555
hereditary breast (549) 549
case-control studies (545) 545
mastectomy (537) 537
cell biology (533) 533
prevention (532) 532
mutation - genetics (515) 515
dna (505) 505
deoxyribonucleic acid--dna (502) 502
mutation carriers (494) 494
ovarian neoplasms - prevention & control (489) 489
chemotherapy (488) 488
health risk assessment (488) 488
brca2 protein - metabolism (477) 477
mammography (471) 471
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10002) 10002
French (141) 141
German (82) 82
Spanish (40) 40
Japanese (37) 37
Russian (33) 33
Chinese (27) 27
Czech (23) 23
Polish (16) 16
Korean (14) 14
Dutch (9) 9
Hungarian (8) 8
Hebrew (5) 5
Croatian (4) 4
Danish (4) 4
Bulgarian (3) 3
Portuguese (3) 3
Swedish (3) 3
Italian (2) 2
Persian (2) 2
Arabic (1) 1
Finnish (1) 1
Icelandic (1) 1
Latvian (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 386 - 391
Abstract Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2 . We... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA1, BRCA2 mutation | Toxicity | Veliparib | PARP inhibitor | Phase II trial | Ovarian cancer | SENSITIVITY | OPEN-LABEL | COMBINATION | PLATINUM-FREE INTERVAL | SOMATIC MUTATIONS | OBSTETRICS & GYNECOLOGY | OLAPARIB | ONCOLOGY | RESISTANCE | HOMOLOGOUS RECOMBINATION | REFRACTORY SOLID TUMORS | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Genes, BRCA1 | Benzimidazoles - adverse effects | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Benzimidazoles - therapeutic use | Fallopian Tube Neoplasms - drug therapy | Medical research | Cancer patients | Care and treatment | Gene mutations | Analysis | Medicine, Experimental | Genetic aspects | Cancer | Chemotherapy | Clinical trials | Index Medicus | toxicity | BRCA2 mutation | ovarian cancer | veliparib | BRCA1
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2014, Volume 371, Issue 6, pp. 497 - 506
Journal Article
Journal Article
by Antoniou, Antonis C and Sinilnikova, Olga M and Simard, Jacques and Léoné, Mélanie and Dumont, Martine and Neuhausen, Susan L and Struewing, Jeffery P and Stoppa-Lyonnet, Dominique and Barjhoux, Laure and Hughes, David J and Coupier, Isabelle and Belotti, Muriel and Lasset, Christine and Bonadona, Valérie and Bignon, Yves-Jean and Rebbeck, Timothy R and Wagner, Theresa and Lynch, Henry T and Domchek, Susan M and Nathanson, Katherine L and Garber, Judy E and Weitzel, Jeffrey and Narod, Steven A and Tomlinson, Gail and Olopade, Olufunmilayo I and Godwin, Andrew and Isaacs, Claudine and Jakubowska, Anna and Lubinski, Jan and Gronwald, Jacek and Górski, Bohdan and Byrski, Tomasz and Huzarski, Tomasz and Peock, Susan and Cook, Margaret and Baynes, Caroline and Murray, Alexandra and Rogers, Mark and Daly, Peter A and Dorkins, Huw and Schmutzler, Rita K and Versmold, Beatrix and Engel, Christoph and Meindl, Alfons and Arnold, Norbert and Niederacher, Dieter and Deissler, Helmut and Spurdle, Amanda B and Chen, Xiaoqing and Waddell, Nicola and Cloonan, Nicole and Kirchhoff, Tomas and Offit, Kenneth and Friedman, Eitan and Kaufmann, Bella and Laitman, Yael and Galore, Gilli and Rennert, Gad and Lejbkowicz, Flavio and Raskin, Leon and Andrulis, Irene L and Ilyushik, Eduard and Ozcelik, Hilmi and Devilee, Peter and Vreeswijk, Maaike P.G and Greene, Mark H and Prindiville, Sheila A and Osorio, Ana and Benítez, Javier and Zikan, Michal and Szabo, Csilla I and Kilpivaara, Outi and Nevanlinna, Heli and Hamann, Ute and Durocher, Francine and Arason, Adalgeir and Couch, Fergus J and Easton, Douglas F and Chenevix-Trench, Georgia and Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab) and German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC) and Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO) and Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE) and Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
The American Journal of Human Genetics, ISSN 0002-9297, 2007, Volume 81, Issue 6, pp. 1186 - 1200
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 27 - 28
The BRCA1 and BRCA2 act as biological markers for early detection of breast and ovarian cancer in women. The risks and benefits of mastectomy before... 
BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | Care and treatment | Usage | Gene mutations | Mastectomy | Breast cancer | Genetic aspects | Research | Biological markers | Risk factors | Genetic screening | Ovarian cancer | Carriers | BRCA2 protein | Chemotherapy | BRCA1 protein | Health risks | Risk reduction | Risk | Mutation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 523 - 533
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2006, Volume 98, Issue 23, pp. 1694 - 1706
Background. BRCA1 and BRCA2 mutations in general populations and in various types of cancers have not been well characterized. We investigated the presence of... 
BREAST-CANCER | SOUTHERN SWEDEN | 6174DELT MUTATION | ONCOLOGY | ASHKENAZI JEWISH CARRIERS | FAMILY-HISTORY DATA | GERMLINE MUTATIONS | SPORADIC OVARIAN-CANCER | 185DELAG MUTATION | CALCULATING PENETRANCE | FOUNDER MUTATIONS | Breast Neoplasms, Male - genetics | Gene Frequency | Humans | Male |